The Company is proud to collaborate on a number
of additional initiatives during the month of May
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced its support of key skin cancer advocacy events and
initiatives throughout May in honor of Skin Cancer Awareness Month.
The first such event is a ribbon cutting to honor the City of
Friendswood’s designation as a Sun Safe Leadership Model
City — the first in Texas — by IMPACT Melanoma. The
ribbon cutting will take place at Stevenson Park in Friendswood,
Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time.
“Skin cancer is the most common cancer in the United States,
with more annual diagnoses than all other cancers combined, but it
is also one of the most preventable, by practicing sun safety and
limiting exposure to UV rays,”1,2 said Derek Maetzold, president
and chief executive officer of Castle Biosciences. “As a long-time
Friendswood resident, both personally and professionally, and as a
steadfast advocate and board member of IMPACT Melanoma, I cannot
think of a better way to honor Skin Cancer Awareness Month than by
partnering with this great organization to showcase our joint
commitment to sun safety and skin cancer prevention.”
The City of Friendswood’s Sun Safe Leadership initiative
encompasses multiple IMPACT programs being implemented throughout
the community, including the installation of sunscreen dispensers
for access to free sunscreen and portable shade tents in city
parks, prevention education for families, and ultraviolet
protection factor (UPF) protective clothing for outdoor workers,
including Parks & Recreation and city employees.
“As a Partner in Prevention with IMPACT Melanoma, Castle
Biosciences is helping to raise awareness of the importance of
being sun safe year-round to help prevent future skin cancer
diagnoses,” said Deb Girard, Executive Director at IMPACT Melanoma.
“We are grateful for Castle’s continued support, equipping families
and communities with the knowledge and resources to truly embrace
sun safety practices.”
Friendswood Mayor and former NASA astronaut, Mike Foreman, will
open the ribbon cutting with brief remarks followed by an award
presentation for the city of Friendswood. “May is Skin Cancer
Awareness Month, a time to educate people about the dangers of skin
cancer, share information and help save lives. That is why the City
of Friendswood is proud to partner with IMPACT Melanoma and Castle
Biosciences to designate Friendswood as a Sun Safe Leadership Model
City,” said Foreman. “We look forward to spreading awareness and
information to our residents, families and friends, and protecting
those we care about.”
Local melanoma survivor, Anne Ramsey, will also take part in the
celebration to share her melanoma journey. “I am honored to join
the City of Friendswood, IMPACT Melanoma and Castle Biosciences to
help inaugurate the Sun Safe City program in Texas. I hope that by
sharing my story, I can inspire others to prioritize skin cancer
prevention and make regular skin checks part of their normal health
regimens.”
Additional initiatives Castle is supporting during Skin
Cancer Awareness Month:
The Skin Cancer Foundation
The Champions for Change Gala is The Skin Cancer
Foundation’s signature fundraising event, being held on May 15 in
New York City. Proceeds from this event, in which Castle is a
sponsor for the third consecutive year, will support the
Foundation’s lifesaving educational campaigns, community programs
and research initiatives.
The Sun Bus
As a platinum sponsor, Castle is proud to support The Sun Bus
for the fourth consecutive year. Kicking off May events, The Sun
Bus will spend several days at NASCAR in Kansas City before heading
west for five additional stops throughout Colorado. Launched by the
Colorado Melanoma Foundation in 2019, The Sun Bus is a mobile
clinic and classroom that provides free skin screenings, skin
cancer awareness and sun safety education to residents across
several southwestern states in the United States.
The Sun Bus launched its 2024 tour in February and plans to make
more than 40 stops during its 10-state tour, including
several days at NASCAR events in Kansas City and Phoenix, before
wrapping up in November. See the 2024 Sun Bus itinerary here.
AIM at Melanoma
Castle is a proud industry sponsor for AIM at Melanoma, whose
goal is to end melanoma in our lifetime while improving the lives
of those it affects. Castle is a national sponsor of their 2024
Steps Against Melanoma Walks throughout May, including those
in Alabama, Pennsylvania, California and Texas. Melanoma survivor
Ramsey is the chair for the Houston walk, happening June 8. Visit
the AIM at Melanoma website for additional information about
upcoming walks.
The Melanoma Research Foundation (MRF)
Castle is also collaborating with the MRF on key educational and
fundraising events taking place during the month of May and beyond,
including, for the fourth consecutive year, the MRF Miles for
Melanoma 5K run/walks. Castle is sponsoring the Boston and
Washington, D.C., walks in May, as well as several others
throughout the year. Visit the Miles for Melanoma website for
information.
Additionally, Castle is participating in the MRF Patient
Symposia Educational Series, including three patient and
caregiver symposia in May. More information can be found here.
The Balancing Act® Airing on Lifetime TV®
Also in May, Castle is collaborating with The Balancing Act
airing on Lifetime TV, to spread the word about the risks and
impacts of skin cancer. In the segment, hosts Olga Villaverde and
Montel Williams will interview Dr. David Cotter, M.D., Ph.D.,
dermatologist at Las Vegas Dermatology, to discuss skin cancer
prevention, risk factors and emerging technologies, including
Castle’s DecisionDx®-Melanoma and DecisionDx®-SCC tests that
identify a patient’s risk of recurrence and metastasis. Julie Bain,
skin cancer survivor and the senior director of science and
education at The Skin Cancer Foundation, will also share her skin
cancer journey. The segment will air twice: on May 6 and May 14,
both at 7:30 a.m. Eastern time and Pacific time, and will be
available on demand on the Balancing Act website after the first
broadcast.
About IMPACT Melanoma
IMPACT Melanoma, a national non-profit 501(c)(3) organization,
is the nation’s leading non-profit dedicated to significantly
reducing melanoma in the United States and saving lives. The focus
is on prevention education programs that include customized and
integrated programs for communities. In addition to skin cancer
prevention education and programs, the organization is committed to
supporting melanoma patients and their families and advocating for
and influencing urban development policies to address shade equity
in America. To learn more about IMPACT Melanoma, visit
https://impactmelanoma.org/.
About The Skin Cancer Foundation
The Skin Cancer Foundation saves and improves lives by
empowering people to take a proactive approach to daily sun
protection and the early detection and treatment of skin cancer.
The mission of the Foundation is to decrease the incidence of skin
cancer through public and professional education and research.
Since its inception in 1979, the Foundation has recommended
following a complete sun protection regimen that includes seeking
shade and covering up with clothing, including a wide-brimmed hat
and UV-blocking sunglasses, in addition to daily sunscreen use. For
more information, visit SkinCancer.org.
About The Sun Bus
The Sun Bus is a mobile classroom and clinic that offers a sun
safety education experience that hyper-targets select audiences at
varying times throughout the year. The program was launched by the
Colorado Melanoma Foundation in 2019 in an effort to better address
their mission of bringing free skin exams and public education to
its Colorado residents. Since then, it has expanded its tour to
reach 10 states, and through its combined 2021, 2022 and 2023
efforts, more than 5,456 Sun Bus visitors were screened for skin
cancer by volunteer physicians. For more information and a calendar
of tour locations, visit TheSunBus.org.
About AIM at Melanoma
Founded in 2004, AIM at Melanoma is a global foundation
dedicated to finding more effective treatments and, ultimately, the
cure for melanoma. By directing and funding paradigm-shifting
research initiatives; educating patients, healthcare professionals
and the public; and advocating for survivors and their families,
AIM at Melanoma’s goal is to end this disease in our lifetime while
improving the lives of those it affects. AIM's work is advancing
the battle against melanoma by focusing on three critical areas:
innovative and collaborative research; legislation, policy and
advocacy; and education. For more information, visit
AimAtMelanoma.org.
About the Melanoma Research Foundation
The Melanoma Research Foundation (MRF) is the largest
independent organization devoted to melanoma. Committed to the
support of medical research to develop effective treatments and
eventually a cure for melanoma, the MRF also educates patients and
physicians about the prevention, diagnosis and treatment of
cutaneous melanoma and the melanoma rare subtypes. The MRF is a
dedicated advocate for the melanoma community, helping to raise
awareness of this disease and the need for a cure. The MRF’s
website is the premier source for melanoma information seekers.
More information is available at Melanoma.org.
About The Balancing Act
The Balancing Act® is a morning show created and produced by
BrandStar that offers sensible solutions and essential information
in a fun, entertaining format; providing resources to help people
do life better. The Balancing Act features everything from
delicious recipes, style makeovers and dream getaways to parenting
tips and the latest news in health and wealth. Tune in to The
Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime® and find
all previously aired episodes on TheBalancingAct.com.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
- The Skin Cancer Foundation;
https://www.skincancer.org/skin-cancer-information/skin-cancer-facts/;
accessed 4/30/24
- Prevent Cancer Foundation;
https://www.preventcancer.org/preventable-cancer/skin-cancer/;
accessed 4/30/24
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430859937/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Jul 2023 to Jul 2024